243 related articles for article (PubMed ID: 37421494)
1. Evaluation of direct oral anticoagulants versus low molecular weight heparins for venous thromboembolism treatment in patients with gastrointestinal malignancies.
Guan T; Laguna A; Soares A; Legasto CS; Block S; Saunders IM; Alvarez K; Pon T; Patel N; Mahajan A; Lee A
J Thromb Thrombolysis; 2023 Oct; 56(3):439-446. PubMed ID: 37421494
[TBL] [Abstract][Full Text] [Related]
2. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.
Kahale LA; Hakoum MB; Tsolakian IG; Matar CF; Terrenato I; Sperati F; Barba M; Yosuico VE; Schünemann H; Akl EA
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD006650. PubMed ID: 29920657
[TBL] [Abstract][Full Text] [Related]
3. Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin and Recurrent VTE in Patients With Cancer: A Randomized Clinical Trial.
Schrag D; Uno H; Rosovsky R; Rutherford C; Sanfilippo K; Villano JL; Drescher M; Jayaram N; Holmes C; Feldman L; Zattra O; Farrar-Muir H; Cronin C; Basch E; Weiss A; Connors JM;
JAMA; 2023 Jun; 329(22):1924-1933. PubMed ID: 37266947
[TBL] [Abstract][Full Text] [Related]
4. Direct oral anticoagulants or low-molecular-weight heparins for venous thromboembolism in patients with brain tumors.
Lee A; Oley F; Lo M; Fong R; McGann M; Saunders I; Block S; Mahajan A; Pon TK
Thromb Res; 2021 Dec; 208():148-155. PubMed ID: 34798446
[TBL] [Abstract][Full Text] [Related]
5. Safety of Direct Oral Anticoagulants in Central Nervous System Malignancies.
Swartz AW; Drappatz J
Oncologist; 2021 May; 26(5):427-432. PubMed ID: 33523555
[TBL] [Abstract][Full Text] [Related]
6. Direct oral anticoagulants in patients with venous thromboembolism and hematological malignancies.
Robinson R; Spectre G; Lishner M; Sharabi O; Robinson E; Hamburger Avnery O; Gafter-Gvili A; Raanani P; Leader A
J Thromb Thrombolysis; 2023 May; 55(4):729-736. PubMed ID: 36943661
[TBL] [Abstract][Full Text] [Related]
7. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for the treatment of cancer-associated thrombosis (which agent for which patient).
Pernod G; Joly M; Sonnet B
J Med Vasc; 2020 Nov; 45(6S):6S17-6S23. PubMed ID: 33276939
[TBL] [Abstract][Full Text] [Related]
8. Risk of intracranial hemorrhage with direct oral anticoagulants vs low molecular weight heparin in glioblastoma: A retrospective cohort study.
Reed-Guy L; Desai AS; Phillips RE; Croteau D; Albright K; O'Neill M; Brem S; O'Rourke DM; Amankulor NM; Bagley SJ
Neuro Oncol; 2022 Dec; 24(12):2172-2179. PubMed ID: 35551405
[TBL] [Abstract][Full Text] [Related]
9. Do women with venous thromboembolism bleed more than men during anticoagulation? Data from the real-life, prospective START-Register.
Palareti G; Legnani C; Antonucci E; Cosmi B; Falanga A; Poli D; Mastroiacovo D; Pengo V; Ageno W; Testa S
Ther Adv Drug Saf; 2021; 12():20420986211062965. PubMed ID: 34987749
[TBL] [Abstract][Full Text] [Related]
10. Treatment of venous thromboembolism in patients with cancer: A network meta-analysis comparing efficacy and safety of anticoagulants.
Posch F; Königsbrügge O; Zielinski C; Pabinger I; Ay C
Thromb Res; 2015 Sep; 136(3):582-9. PubMed ID: 26210891
[TBL] [Abstract][Full Text] [Related]
11. Anticoagulant prescribing patterns in patients with primary central nervous system malignancies and secondary metastases.
Abdelmessih E; Ahuja T; Wo S; Sango A; Papadopoulos J; Green D; Xiang E
J Thromb Thrombolysis; 2024 Mar; 57(3):418-427. PubMed ID: 38281232
[TBL] [Abstract][Full Text] [Related]
12. DOAC compared to LMWH in the treatment of cancer related-venous thromboembolism: a systematic review and meta-analysis.
Mai V; Tanguay VF; Guay CA; Bertoletti L; Magnan S; Turgeon AF; Lacasse Y; Lega JC; Provencher S
J Thromb Thrombolysis; 2020 Oct; 50(3):661-667. PubMed ID: 32052314
[TBL] [Abstract][Full Text] [Related]
13. The Role of Direct Oral Anticoagulants in the Treatment of Cancer-Associated Venous Thromboembolism: Review by Middle East and North African Experts.
Bazarbashi S; El Zawahry HM; Owaidah T; AlBader MA; Warsi A; Marashi M; Dawoud E; Jaafar H; Sholkamy SM; Haddad F; Cohen AT
J Blood Med; 2024; 15():171-189. PubMed ID: 38686358
[TBL] [Abstract][Full Text] [Related]
14. Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants.
Ay C; Beyer-Westendorf J; Pabinger I
Ann Oncol; 2019 Jun; 30(6):897-907. PubMed ID: 30918939
[TBL] [Abstract][Full Text] [Related]
15. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis.
Li A; Garcia DA; Lyman GH; Carrier M
Thromb Res; 2019 Jan; 173():158-163. PubMed ID: 29506866
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats.
O'Connell C; Escalante CP; Goldhaber SZ; McBane R; Connors JM; Raskob GE
Oncologist; 2021 Jan; 26(1):e8-e16. PubMed ID: 33275319
[TBL] [Abstract][Full Text] [Related]
17. Safety and Efficacy of Direct Oral Anticoagulant Therapy in Patients With Cancer.
Fovel LM; Seabury RW; Miller CD; Darko W; Probst LA; Horvath L
J Pharm Pract; 2021 Oct; 34(5):710-714. PubMed ID: 31888399
[TBL] [Abstract][Full Text] [Related]
18. OC-13 - Safe and effective use of direct oral anticoagulants (DOAC) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism.
Ross JA; Miller M; Hernandez CR
Thromb Res; 2016 Apr; 140 Suppl 1():S173-4. PubMed ID: 27161685
[TBL] [Abstract][Full Text] [Related]
19. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Rutjes AW; Porreca E; Candeloro M; Valeriani E; Di Nisio M
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD008500. PubMed ID: 33337539
[TBL] [Abstract][Full Text] [Related]
20. Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism.
Giustozzi M; Franco L; Vedovati MC; Becattini C; Agnelli G
J Thromb Thrombolysis; 2019 Oct; 48(3):439-453. PubMed ID: 31104194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]